SCHEDULE: Acorn Bioventures Discloses 5.2% Stake in Athira Pharma

Acorn Bioventures and related entities, including Anders Hove, reported a combined beneficial ownership of 5.2% in Athira Pharma, Inc. common stock.

Summary

• Acorn Bioventures, L.P. and Acorn Capital Advisors GP, LLC each beneficially own 210,730 shares of Athira Pharma, Inc. common stock, representing 2.2% of the class.
• Acorn Bioventures 2, L.P. and Acorn Capital Advisors GP 2, LLC each beneficially own 291,009 shares of Athira Pharma, Inc. common stock, representing 3.0% of the class.
• Anders Hove, as Manager of the general partners for both Acorn Bioventures funds, is deemed to beneficially own an aggregate of 501,739 shares, representing 5.2% of Athira Pharma, Inc. common stock.
• The beneficial ownership percentages are calculated based on 9,604,313 shares of Common Stock outstanding as of November 18, 2025.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Athira Pharma, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure, indicating a neutral sentiment as it does not contain performance data or strategic changes.

Future Outlook

NA

Industry Context

This filing represents a routine disclosure of beneficial ownership by an investment firm in a biotechnology company. Such disclosures are common and provide transparency regarding significant investor stakes, which can be of interest to other investors tracking institutional positions in the biotech sector.

Stakeholder Impact

• Increased transparency regarding a significant institutional investor's stake in Athira Pharma, providing insight for other shareholders and potential investors.

Key Dates

Keywords

Athira Pharma, Acorn Bioventures, Anders Hove, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment